93 related articles for article (PubMed ID: 15388474)
1. Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.
Hoellman DB; Pankuch GA; Appelbaum PC
Antimicrob Agents Chemother; 2004 Oct; 48(10):4037-9. PubMed ID: 15388474
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci.
Huang V; Brown WJ; Rybak MJ
Antimicrob Agents Chemother; 2004 Jul; 48(7):2719-23. PubMed ID: 15215134
[TBL] [Abstract][Full Text] [Related]
3. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
[TBL] [Abstract][Full Text] [Related]
4. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.
Lin G; Credito K; Ednie LM; Appelbaum PC
Antimicrob Agents Chemother; 2005 Feb; 49(2):770-2. PubMed ID: 15673763
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
6. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
Credito K; Lin G; Ednie LM; Appelbaum PC
Antimicrob Agents Chemother; 2004 Oct; 48(10):4033-6. PubMed ID: 15388473
[TBL] [Abstract][Full Text] [Related]
7. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
Bogdanovich T; Ednie LM; Shapiro S; Appelbaum PC
Antimicrob Agents Chemother; 2005 Oct; 49(10):4210-9. PubMed ID: 16189100
[TBL] [Abstract][Full Text] [Related]
8. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
[TBL] [Abstract][Full Text] [Related]
9. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
Lin G; Appelbaum PC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):233-5. PubMed ID: 17997257
[TBL] [Abstract][Full Text] [Related]
10. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
11. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
12. Antistaphylococcal activity of the novel cephalosporin CB-181963 (CAB-175).
Miller K; Storey C; Stubbings WJ; Hoyle AM; Hobbs JK; Chopra I
J Antimicrob Chemother; 2005 Apr; 55(4):579-82. PubMed ID: 15722396
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
[TBL] [Abstract][Full Text] [Related]
14. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
Leuthner KD; Cheung CM; Rybak MJ
J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
[TBL] [Abstract][Full Text] [Related]
16. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
Strukova EN; Smirnova MV; Vostrov SN; Lubenko IY; Firsov AA; Zinner SH; Portnoy YA
Int J Antimicrob Agents; 2009 Mar; 33(3):251-4. PubMed ID: 19095420
[TBL] [Abstract][Full Text] [Related]
17. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
Patel MV; De Souza NJ; Gupte SV; Jafri MA; Bhagwat SS; Chugh Y; Khorakiwala HF; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftobiprole, linezolid, tigecycline, and 23 other antimicrobial agents against Staphylococcus aureus isolates in China.
Wang H; Liu Y; Sun H; Xu Y; Xie X; Chen M
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):226-9. PubMed ID: 18653301
[TBL] [Abstract][Full Text] [Related]
19. In vitro antibacterial activity of TOC-50, a new parenteral cephalosporin against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
Nomura S; Hanaki H; Unemi N
Chemotherapy; 1996; 42(4):253-8. PubMed ID: 8804792
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
